Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets
D6402C00012
Phase 3 small_molecule active
Quick answer
Balcinrenone+Dapagliflozin, Balcinrenone+Dapagliflozin, Forxiga, Balcinrenone+Dapagliflozin, Forxiga 10 mg film-coated tablets for Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active